Literature DB >> 10066380

Analysis of Tax-expressing cell lines generated from HTLV-I tax-transgenic mice: correlation between c-myc overexpression and neoplastic potential.

D Saggioro1, D M D'agostino, L Chieco-Bianchi.   

Abstract

Human T-cell leukemia/lymphotropic virus type I (HTLV-I) infection causes a variety of human diseases, including adult T-cell leukemia/lymphoma. The viral transactivator Tax has been implicated as a key factor in the HTLV-I-induced transformation pathway. To investigate the components of this pathway, we derived fibroblast-like cell lines, designated T6 and T9, from tail biopsies of tax-transgenic C57BL/6 mice that do not develop tumors. Phenotypic characterization of T6 and T9 cells and T6-derived subclones revealed that they differ in their abilities to form foci in vitro and tumors in vivo. The observed differences in the levels of Tax expression did not correlate with their degree of neoplastic potential. However, a control cell line derived from a nontransgenic C57BL/6 mouse did not form foci in vitro or tumors in vivo, indicating that Tax was required for the transformation process. Results of Northern analyses showed that the T9 cells and the highly malignant derivatives of T6 cells expressed elevated levels of c-myc mRNA. These findings suggest that progression of the tax-transgenic cells toward a more malignant phenotype might involve c-myc deregulation. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10066380     DOI: 10.1006/excr.1998.4381

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  5 in total

1.  Discordance between bovine leukemia virus tax immortalization in vitro and oncogenicity in vivo.

Authors:  J C Twizere; P Kerkhofs; A Burny; D Portetelle; R Kettmann; L Willems
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30(II) accessory protein and the induction of oncogenic cellular transformation by p30(II)/c-MYC.

Authors:  Megan M Romeo; Bookyung Ko; Janice Kim; Rebecca Brady; Hayley C Heatley; Jeffrey He; Carolyn K Harrod; Braden Barnett; Lee Ratner; Michael D Lairmore; Ernest Martinez; Bernhard Lüscher; Craig N Robson; Marie Henriksson; Robert Harrod
Journal:  Virology       Date:  2015-01-05       Impact factor: 3.616

3.  A human T-cell lymphotropic virus type 1 enhancer of Myc transforming potential stabilizes Myc-TIP60 transcriptional interactions.

Authors:  Soumya Awasthi; Anima Sharma; Kasuen Wong; Junyu Zhang; Elizabeth F Matlock; Lowery Rogers; Pamela Motloch; Shigeki Takemoto; Hirokuni Taguchi; Michael D Cole; Bernhard Lüscher; Oliver Dittrich; Hideaki Tagami; Yoshihiro Nakatani; Monnie McGee; Anne-Marie Girard; Luke Gaughan; Craig N Robson; Raymond J Monnat; Robert Harrod
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

4.  HTLV-I Tax-dependent and -independent events associated with immortalization of human primary T lymphocytes.

Authors:  Marcia Bellon; Hicham H Baydoun; Yuan Yao; Christophe Nicot
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

5.  HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase.

Authors:  Sarah S Durkin; Xin Guo; Kimberly A Fryrear; Valia T Mihaylova; Saurabh K Gupta; S Mehdi Belgnaoui; Abdelali Haoudi; Gary M Kupfer; O John Semmes
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.